Suzano (SUZB3) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
1 Feb, 2026Executive summary
Adjusted EBITDA reached R$6.3 billion, up 38% from 1Q24 and 60% year-over-year, with strong operational performance and cash generation, initiating a deleveraging cycle.
Strategic investments included a 15% stake in Lenzing (EUR230 million) and entry into the US packaging market via Pactiv, supporting downstream and international growth.
The Cerrado Project, the world's largest single-line pulp mill, began operations on time and on budget, with ramp-up underway and 900,000 tons expected in 2024.
Financial highlights
Adjusted EBITDA was R$6.3 billion, up from R$4.6 billion in 1Q24 and R$3.9 billion in 2Q23, with EBITDA margin rising to 55%.
Net revenue reached R$11.5 billion, up 22% sequentially and 25% year-over-year, with 80% from exports.
Net income was a loss of R$3.77 billion, mainly due to BRL depreciation and derivative losses.
Free cash flow (adjusted) was R$1.92 billion, up 7% from 1Q24 but down 64% year-over-year.
Capex totaled R$3.96 billion, focused on the Cerrado Project and maintenance.
Outlook and guidance
The Cerrado Project is expected to produce 900,000 tons in 2024 and reach 2 million tons annualized within 12 months.
Focus remains on maximizing long-term returns, maintaining financial discipline, and no refinancing risk until 2029.
Total operational expenditure for pulp is forecast at R$1,750/ton by 2027.
Cash costs projected to remain stable ex-downtime, with improvement expected post-Cerrado ramp-up.
Latest events from Suzano
- Record sales, cost discipline, and strong liquidity support a positive outlook.SUZB3
Q4 202511 Feb 2026 - EBITDA and sales volumes surged, with Ribas ramp-up and acquisitions boosting performance.SUZB3
Q3 202418 Jan 2026 - Cost leadership, operational excellence, and disciplined capital allocation drive growth.SUZB3
Investor Day 202411 Jan 2026 - Record sales and EBITDA driven by Ribas ramp-up, but FX losses led to a net loss.SUZB3
Q4 20248 Jan 2026 - Focus is on competitiveness, cost reduction, and disciplined growth amid market shifts.SUZB3
Investor Day 202512 Dec 2025 - Strong sales growth, robust cash flow, and major strategic moves marked the quarter.SUZB3
Q2 202523 Nov 2025 - Net income rose to R$6.3B in 1Q25, with stable leverage and strong free cash flow.SUZB3
Q1 202518 Nov 2025 - JV creates a global tissue leader with $3.3bn revenue, $175M synergies, and strong diversification.SUZB3
Investor Update12 Nov 2025 - Cash cost below BRL 800/ton, EBITDA down 20%, leverage up, 2025 capex guidance reaffirmed.SUZB3
Q3 20257 Nov 2025